P Sinha1, W T Thorstad2, B Nussenbaum1, B H Haughey1, D R Adkins3, D Kallogjeri1, J S Lewis4. 1. Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA. 2. Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 3. Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA. 4. Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA; Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: jlewis@path.wustl.edu.
Abstract
OBJECTIVE: With good loco-regional control, disease failure in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) mainly results from distant metastasis (DM). Our objective was to characterize the patterns and clinical outcomes of DM in p16-positive OPSCC and compare these to patients with p16-negative disease. METHODS: Primary OPSCC patients who developed DM after completing surgical or non-surgical treatment were identified and p16 status was evaluated. Patterns of DM and post-DM progression-free (PFS) and disease-specific survival (DSS) were assessed. RESULTS: Forty-one of the 66 (62%) patients with DM were p16-positive. DM patterns were not statistically different by p16 status. However, p16-positive patients developed DM later in their course and had longer survival. All p16-negative patients either had progression or died within 24 months of DM detection whereas the 2-year post-DM PFS in the p16-positive group was 20% (95% CI: 8-32.5%, p=0.003). The 3-year post-DM disease-specific survival (DSS) estimate in the p16-positive patients was 16% (95% CI: 7-18%) while all p16-negative patients died within 34 months (p<0.001). p16-negativity, loco-regional disease, and no/palliative versus curative intent treatment were all associated with reduced post-DM DSS in multivariate analysis. CONCLUSIONS: The DM pattern did not differ remarkably between p16-positive and negative OPSCC patients in our practice. In p16-positive OPSCC with pulmonary oligometastatic disease, curative intent treatment and optimized locoregional control for the index primary prolonged survival.
OBJECTIVE: With good loco-regional control, disease failure in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) mainly results from distant metastasis (DM). Our objective was to characterize the patterns and clinical outcomes of DM in p16-positive OPSCC and compare these to patients with p16-negative disease. METHODS: Primary OPSCC patients who developed DM after completing surgical or non-surgical treatment were identified and p16 status was evaluated. Patterns of DM and post-DM progression-free (PFS) and disease-specific survival (DSS) were assessed. RESULTS: Forty-one of the 66 (62%) patients with DM were p16-positive. DM patterns were not statistically different by p16 status. However, p16-positive patients developed DM later in their course and had longer survival. All p16-negative patients either had progression or died within 24 months of DM detection whereas the 2-year post-DM PFS in the p16-positive group was 20% (95% CI: 8-32.5%, p=0.003). The 3-year post-DM disease-specific survival (DSS) estimate in the p16-positive patients was 16% (95% CI: 7-18%) while all p16-negative patients died within 34 months (p<0.001). p16-negativity, loco-regional disease, and no/palliative versus curative intent treatment were all associated with reduced post-DMDSS in multivariate analysis. CONCLUSIONS: The DM pattern did not differ remarkably between p16-positive and negative OPSCC patients in our practice. In p16-positive OPSCC with pulmonary oligometastatic disease, curative intent treatment and optimized locoregional control for the index primary prolonged survival.
Authors: James S Lewis; Rebecca D Chernock; Xiao-Jun Ma; John J Flanagan; Yuling Luo; Ge Gao; Xiaowei Wang; Samir K El-Mofty Journal: Mod Pathol Date: 2012-05-18 Impact factor: 7.842
Authors: Shao Hui Huang; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Hope; Christine Massey; John N Waldron; John Kim; Andrew J Bayley; Bernard Cummings; B C John Cho; Jolie Ringash; Laura A Dawson; Lillian L Siu; Eric Chen; Jonathan Irish; Patrick Gullane; Angela Hui; Fei-Fei Liu; Xiaowei Shen; Wei Xu; Brian O'Sullivan Journal: Oral Oncol Date: 2012-08-20 Impact factor: 5.337
Authors: Azeem S Kaka; Bhavna Kumar; Pawan Kumar; Paul E Wakely; Claudia M Kirsch; Matthew O Old; Enver Ozer; Amit Agrawal; Ricardo E Carrau; David E Schuller; Farzan Siddiqui; Theodoros N Teknos Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2013-06-14
Authors: S A Leibel; C B Scott; M Mohiuddin; V A Marcial; L R Coia; L W Davis; Z Fuks Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: Glenn J Hanna; Alec Kacew; Nicole G Chau; Priyanka Shivdasani; Jochen H Lorch; Ravindra Uppaluri; Robert I Haddad; Laura E MacConaill Journal: JCI Insight Date: 2018-09-06
Authors: Philipp Baumeister; Maximilian Reiter; Christian Welz; Sven Becker; Christian Betz; Ulrich Harréus Journal: J Cancer Res Clin Oncol Date: 2014-03-11 Impact factor: 4.553
Authors: Thomas S Frank; Xiaotian Sun; Yuqing Zhang; Jingxuan Yang; William E Fisher; Marie-Claude Gingras; Min Li Journal: Cancer Lett Date: 2015-04-15 Impact factor: 8.679
Authors: Natalie M Lowe; Jonathan M Bernstein; Kathleen Mais; Kate Garcez; Lip W Lee; Andrew Sykes; David J Thomson; Jarrod J Homer; Catharine M West; Nicholas J Slevin Journal: J Cancer Res Clin Oncol Date: 2017-12-08 Impact factor: 4.553
Authors: B H Haughey; P Sinha; D Kallogjeri; R L Goldberg; J S Lewis; J F Piccirillo; R S Jackson; E J Moore; M Brandwein-Gensler; S J Magnuson; W R Carroll; T M Jones; M D Wilkie; A Lau; N S Upile; Jon Sheard; J Lancaster; S Tandon; M Robinson; D Husband; I Ganly; J P Shah; D M Brizel; B O'Sullivan; J A Ridge; W M Lydiatt Journal: Oral Oncol Date: 2016-09-23 Impact factor: 5.337
Authors: Craig A Bollig; Christopher I Newberry; Tabitha L I Galloway; Robert P Zitsch; Elyse K Hanly; Vivian L Zhu; Nitin Pagedar; Rohit Nallani; Andres M Bur; William C Spanos; Jeffrey B Jorgensen Journal: Laryngoscope Date: 2020-10-24 Impact factor: 3.325